TECH BIO-TECHNE Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$56.67

Market cap

$8.87B

P/E Ratio

79.82

Dividend/share

$0.32

EPS

$0.71

Enterprise value

$8.95B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 46
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 59

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
BIO-TECHNE's debt has decreased by 31% YoY and by 17% QoQ
The quick ratio has increased by 24% year-on-year and by 9% since the previous quarter
TECH's EPS is up by 37% since the previous quarter but it is down by 14% year-on-year
The net income has increased by 35% from the previous quarter but it has decreased by 17% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.bio-techne.com/
Peers: TMO DHR QGEN BDX

Key stats

What are the main financial stats of TECH

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
1.91%
1 week
1.14%
1 month
17.55%
1 year
14.95%
YTD
-3.64%
QTD
8.44%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.21B
Gross profit
$786.49M
Operating income
$153.75M
Net income
$109.56M
Gross margin
65%
Net margin
9%
The net income has increased by 35% from the previous quarter but it has decreased by 17% YoY
BIO-TECHNE's net margin has increased by 34% QoQ but it has decreased by 17% YoY
BIO-TECHNE's operating margin has increased by 32% QoQ but it has decreased by 11% YoY
The company's operating income rose by 31% QoQ but it fell by 11% YoY

Price vs fundamentals

How does TECH's price correlate with its fundamentals

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
TECH P/E details
P/E
79.82
P/B
4.25
P/S
7.32
EV/EBIT
57.52
EV/EBITDA
34.98
EV/Sales
7.39
TECH's EPS is up by 37% since the previous quarter but it is down by 14% year-on-year
TECH's P/E is 23% below its last 4 quarters average of 101.9 but 6% above its 5-year quarterly average of 74.1
The stock's price to book (P/B) is 38% less than its 5-year quarterly average of 6.7 and 3% less than its last 4 quarters average of 4.3
BIO-TECHNE's equity has increased by 3.7% from the previous quarter and by 3.3% YoY
The price to sales (P/S) is 36% lower than the 5-year quarterly average of 11.2 but 2.6% higher than the last 4 quarters average of 7.0

Efficiency

How efficient is BIO-TECHNE business performance
TECH's return on assets is up by 34% since the previous quarter but it is down by 12% year-on-year
BIO-TECHNE's return on equity has increased by 34% QoQ but it has decreased by 13% YoY
BIO-TECHNE's ROIC has increased by 31% from the previous quarter but it has decreased by 8% YoY
TECH's return on sales is up by 28% since the previous quarter but it is down by 13% year-on-year

Dividends

What is TECH's dividend history
Dividend details
DPS
$0.32
Dividend yield
0.56%
Payout ratio
45.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has decreased by 26% YoY and by 9% QoQ
The quick ratio has increased by 24% year-on-year and by 9% since the previous quarter
BIO-TECHNE's debt is 86% lower than its equity
TECH's debt to equity is down by 33% year-on-year and by 18% since the previous quarter
BIO-TECHNE's debt has decreased by 31% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.